# The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

> **NCT05360615** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chulalongkorn University** · enrollment: 147 (estimated)

## Conditions studied

- Empagliflozin in Post AKI Stage 2-3

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05360615
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05360615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05360615, "The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05360615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*